Eli Lilly and Company's Bydureon Diabetes Drug Recommended by UK Cost Agency
Published: Oct 18, 2011
Eli Lilly & Co. (LLY)’s Bydureon diabetes drug was approved by the U.K.’s health-cost agency for use in combination with two glucose-lowering medicines. Bydureon can be used with metformin and a sulphonylurea, or metformin and a thiazolidinedione, when control of blood sugar is inadequate, the National Institute for Health and Clinical Excellence said in a statement today. Lilly, whose top-selling schizophrenia drug Zyprexa loses U.S. patent protection this month, is seeking clearance to sell Bydureon in the U.S.